Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine Augmentation of CRT in Schizotypal Personality Disorder
NCT02524899Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guanfacine in schizotypal personality disorder (STPD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jan 2014; status: completed.
02
Drugs
guanfacine
03
Conditions
schizotypal personality disorder (STPD)
Beyond the preview
Go deeper on NCT02524899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524899.